Despite initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), most patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations inevitably develop resistance after approximately one year (1, 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.